Amneal gains FDA nod for launch of Revatio® & Amicar® tablets
Category: #health  By Mateen Dalal  Date: 2019-12-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Amneal gains FDA nod for launch of Revatio® & Amicar® tablets

Amneal Pharmaceuticals, Inc. has made some consistent ripples in the generics and specialty pharmaceutical industry. Recently, the company made headlines when it revealed attaining final approval from the U.S. FDA on its ANDA (Abbreviated New Drug Applications) for generic editions of Amicar® (aminocaproic acid) Tablets USP, 500 mg and Revatio® for Oral Suspension 10 mg/ml.

According to a statement, Chintu Patel, Co-CEO, Amneal, said that their company is delighted to introduce these new drugs to healthcare providers and patients. He claims that their firm’s diverse and large pipeline has managed to deliver 36 new generic items in 2019 across multiple dosage forms.

Reportedly, Amneal had earlier bagged the designation of Competitive Generic Therapy (CGT) from the FDA for the generic version of Amicar®. Considering its first approved application, the biotech has been offered 180 days of CGT exclusivity.

Prior to this news, Amneal was in limelight for the launch of the generic version of Invega® (paliperidone). The drug was introduced in extended-release tablets ranging from 1.5mg to 9mg.

Speaking of which, Patel said that the company is pleased to get an approval for the launch of the generic version of Invega. It marks as one of 15 complex drugs that the firm expects to launch over 24-month.

Moreover, with a varied lineup of over 170 products, the company hopes to progress these types of complex product approvals, which would further expand its portfolio. Also, such moves would allow patients to buy generic medicines at affordable prices, cites Patel.

For the record, Amneal Pharmaceuticals, Inc. is based in Bridgewater, New Jersey. It is an integrated pharmaceutical firm focused on manufacturing, developing and distributing branded, generic, and biosimilar products. Amneal has operations in Asia, North America and Europe, and is working on bringing high-quality medicines to patients primarily within the U.S.
 

Source Credit: https://investors.amneal.com/news/press-releases/press-release-details/2019/Amneal-Announces-the-Approval-and-Launch-of-Generic-Revatio-for-Oral-Suspension-and-Generic-Amicar-Tablets/default.aspx

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Snapchat announces the launch of in-app TikTok competitor Spotlight
Snapchat announces the launch of in-app TikTok competitor Spotlight
By Mateen Dalal

Snapchat, an American multimedia messaging platform, has reportedly launched a new section of its application called Spotlight. The new feature will offer surface video content and will allow the company to compete with Chinese video sharing platform...

Google Pay updated to become an all-in-one-bank ahead of Plex launch
Google Pay updated to become an all-in-one-bank ahead of Plex launch
By Mateen Dalal

Google’s digital wallet and online payment system Google Pay has reportedly been updated with a bunch of new features, UI, and a logo. Sources with relevant information claimed that these changes are a result of huge upscaling of Google Pay as ...

Alibaba generates revenues worth USD 74 billion in Singles Day sale
Alibaba generates revenues worth USD 74 billion in Singles Day sale
By Mateen Dalal

Alibaba, a Chinese multinational technology company, has reportedly generated sales worth USD 74 billion in its post COVID-19 Singles’ Day shopping extravaganza. The recent development follows the company recently witnessing a 10% decline in it...